Used as a reference standard for Bromobutene linagliptin impurity VII in pharmaceutical quality control, specifically for the detection and quantification of impurities during the synthesis of linagliptin, a DPP-4 inhibitor. Helps ensure the purity and safety of gliptin-class antidiabetic drugs by identifying potential by-products in manufacturing processes. Employed in analytical testing such as HPLC and mass spectrometry method development.